Active Ingredient(s): Alogliptin + Metformin Hydrochloride
FDA Approved: * January 25, 2013
Pharm Company: * TAKEDA PHARMS USA
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Kazano Overview

Alogliptin, sold under the brand names Nesina and Vipidia,[1][2]) is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class.[3] Alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination wi...

Read more Kazano Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Alogliptin

Recent Kazano Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Alogliptin + Metformin Hydrochloride
  • Tablet: 12.5mg + 1000mg, 12.5mg + 1gm, 12.5mg + 500mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Kazano: (2 results)

Sorted by National Drug Code
  • 64764-335 Kazano 12.5/500 Oral Tablet by Takeda Pharmaceuticals America, Inc.
  • 64764-337 Kazano 12.5/1000 Oral Tablet by Takeda Pharmaceuticals America, Inc.

Drugs with one or more similar ingredients: (30 results)